News
Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for ...
Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...
On a very good Friday for the stock market, Biohaven 's ( BHVN 6.33%) performance was exceptional. The clinical-stage biotech ...
Biohaven (NYSE:BHVN) shares spiked in the premarket on Friday after the FDA revoked an advisory committee meeting scheduled ...
More bad news has come down for Biohaven’s small molecule troriluzole. | More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee ...
1d
Investor's Business Daily on MSNBiohaven Surges After FDA Cancels Key Meeting. But Is It Good News?
Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug, ...
--Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common ...
Shares of Biohaven Ltd. BHVN climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed the progress of the condition in a clinical trial.
Biohaven reported that its novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, demonstrated encouraging preliminary clinical activity ...
A Biohaven Pharmaceuticals drug developed to treat disease by modulating a neurotransmitter that’s important to normal brain function has failed a pivotal study in a rare neuromuscular disorder ...
--Biohaven Pharmaceutical Holding Company Ltd. today announced a Patient Savings Program for NURTEC™ ODT that is now available for eligible commercially insured patients. The U.S. Food and Drug ...
Biohaven Pharmaceutical Holding Company Ltd., parent company of Biohaven Therapeutics, is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results